As of close of business last night, Astrazeneca plc ADR’s stock clocked out at $65.73, down -0.20% from its previous closing price of $65.86. In other words, the price has decreased by -$0.13 from its previous closing price. On the day, 3523475 shares were traded.
Ratios:
To gain a deeper understanding of AZN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 34.18 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.98. For the most recent quarter (mrq), Quick Ratio is recorded 0.64 and its Current Ratio is at 0.82. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.59.
On January 23, 2024, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $85.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AZN now has a Market Capitalization of 200.40B and an Enterprise Value of 223.16B. As of this moment, Astrazeneca’s Price-to-Earnings (P/E) ratio for their current fiscal year is 34.44, and their Forward P/E ratio for the next fiscal year is 14.22. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.69. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.45 while its Price-to-Book (P/B) ratio in mrq is 5.21. Its current Enterprise Value per Revenue stands at 4.87 whereas that against EBITDA is 16.63.
Stock Price History:
The Beta on a monthly basis for AZN is 0.51, which has changed by -2.27% over the last 52 weeks, in comparison to a change of 32.31% over the same period for the S&P500. Over the past 52 weeks, AZN has reached a high of $76.56, while it has fallen to a 52-week low of $60.47. The 50-Day Moving Average of the stock is 65.90, while the 200-Day Moving Average is calculated to be 67.12.
Shares Statistics:
It appears that AZN traded 6.24M shares on average per day over the past three months and 4.68M shares per day over the past ten days. A total of 3.10B shares are outstanding, with a floating share count of 3.10B. Insiders hold about 0.03% of the company’s shares, while institutions hold 15.97% stake in the company. Shares short for AZN as of Feb 29, 2024 were 9.26M with a Short Ratio of 1.48, compared to 4.1M on Jan 31, 2024.
Dividends & Splits
With its trailing 12-month dividend rate of 2.90, AZN has a forward annual dividend rate of 1.45. Against a Trailing Annual Dividend Yield of 4.40%, it implies a Forward Annual Dividend Yield of 2.21%. The stock’s 5-year Average Dividend Yield is 2.55. The current Payout Ratio is 73.87% for AZN, which recently paid a dividend on Mar 25, 2024 with an ex-dividend date of Feb 22, 2024. Stock splits for the company last occurred on Jul 27, 2015 when the company split stock in a 2:1 ratio.
Earnings Estimates
As of right now, 3 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $1.25 for the current quarter, with a high estimate of $1.94 and a low estimate of $0.89, while EPS last year was $0.96. The consensus estimate for the next quarter is $1.35, with high estimates of $1.98 and low estimates of $0.99.
Analysts are recommending an EPS of between $8.03 and $3.06 for the fiscal current year, implying an average EPS of $4.56. EPS for the following year is $5.14, with 6 analysts recommending between $8.93 and $3.52.
Revenue Estimates
In the current quarter, 4 analysts expect revenue to total $11.98B. It ranges from a high estimate of $12.44B to a low estimate of $11.65B. As of the current estimate, Astrazeneca plc ADR’s year-ago sales were $10.55B, an estimated increase of 13.50% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $12.46B, an increase of 13.70% over than the figure of $13.50% in the same quarter last year. There is a high estimate of $12.62B for the next quarter, whereas the lowest estimate is $12.36B.
A total of 8 analysts have provided revenue estimates for AZN’s current fiscal year. The highest revenue estimate was $51.43B, while the lowest revenue estimate was $49.85B, resulting in an average revenue estimate of $50.79B. In the same quarter a year ago, actual revenue was $45.81B, up 10.90% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $54.5B in the next fiscal year. The high estimate is $55.65B and the low estimate is $52.45B. The average revenue growth estimate for next year is up 7.30% from the average revenue estimate for this year.
